Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 14, 2025

CAL-51

RRID:CVCL_1110
Type: Cell Line

Proper Citation

(RRID:CVCL_1110)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1110

Proper Citation: (RRID:CVCL_1110)

Description: Cell line CAL-51 is a Cancer cell line with a species of origin Homo sapiens

Sex: Female

Disease: Breast carcinoma

Defining Citation: PMID:2390488, PMID:10969801, PMID:11044355, PMID:12661003, PMID:12800145, PMID:15677628, PMID:19582160, PMID:20164919, PMID:20215515, PMID:21778573, PMID:22460905, PMID:22585861, PMID:23122841, PMID:24176112, PMID:25485619, PMID:25984343, PMID:27397505, PMID:28196595, PMID:30894373, PMID:31068700, PMID:31978347, PMID:34339474, PMID:35839778

Comments: Derived from metastatic site: Pleural effusion., Misspelling: Ca151; In Cosmic 1057761., Omics: Transcriptome analysis., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep RNAseq analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Microsatellite instability: Instable (MSI-low) (PubMed=12661003; PubMed=15677628; PubMed=31068700; Sanger)., Doubling time: 24 hours (PubMed=25984343); ~30 hours (PubMed=34339474); ~50-60 hours (DSMZ)., Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: GrayJW breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens

Name: CAL-51

Synonyms: CAL 51, CAL51, Cal51, Centre Antoine Lacassagne-51

Cross References: BTO:BTO:0000945, CLO:CLO_0002185, EFO:EFO_0005358, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473159, BioSample:SAMN10988576, Cell_Model_Passport:SIDM00933, ChEMBL-Cells:CHEMBL3308717, ChEMBL-Targets:CHEMBL1075411, Cosmic:687467, Cosmic:910927, Cosmic:1057761, Cosmic:2164986, Cosmic-CLP:910927, DepMap:ACH-000856, DSMZ:ACC-302, DSMZCellDive:ACC-302, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:910927, GEO:GSM115099, GEO:GSM217567, GEO:GSM274645, GEO:GSM274646, GEO:GSM344362, GEO:GSM344412, GEO:GSM350521, GEO:GSM459702, GEO:GSM783973, GEO:GSM827162, GEO:GSM847246, GEO:GSM847456, GEO:GSM886909, GEO:GSM887975, GEO:GSM1172946, GEO:GSM1374429, GEO:GSM1664565, GEO:GSM1669652, IARC_TP53:21211, IGRhCellID:CAL51, LiGeA:CCLE_143, LINCS_HMS:50008, LINCS_LDP:LCL-1472, Lonza:1002, PharmacoDB:CAL51_172_2019, PRIDE:PXD000953, PRIDE:PXD030304, Progenetix:CVCL_1110, PubChem_Cell_line:CVCL_1110, SLKBase:3399, Wikidata:Q54808406

ID: CVCL_1110

Record Creation Time: 20220427T215439+0000

Record Last Update: 20250131T100400+0000

Ratings and Alerts

No rating or validation information has been found for CAL-51.

No alerts have been found for CAL-51.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Zerbib J, et al. (2024) Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. Nature communications, 15(1), 7772.

Wang M, et al. (2024) Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates. Cell chemical biology, 31(12), 2039.

Zhang S, et al. (2024) NEAT1 repression by MED12 creates chemosensitivity in p53 wild-type breast cancer cells. The FEBS journal.

Liu CC, et al. (2024) Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell reports. Medicine, 5(2), 101396.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3298.

Tran DH, et al. (2024) De novo and salvage purine synthesis pathways across tissues and tumors. Cell, 187(14), 3602.

Chappidi N, et al. (2024) PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends. Cell, 187(4), 945.

Tucker JB, et al. (2023) Misaligned Chromosomes are a Major Source of Chromosomal Instability in Breast Cancer. Cancer research communications, 3(1), 54.

Pan F, et al. (2023) FOXM1 is critical for the fitness recovery of chromosomally unstable cells. Cell death & disease, 14(7), 430.

Zelceski A, et al. (2023) MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. Cell reports, 42(5), 112484.

Stanland LJ, et al. (2023) CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer. Molecular cancer research : MCR, 21(11), 1148.

Cáceres-Gutiérrez RE, et al. (2022) Proteasome inhibition alters mitotic progression through the upregulation of centromeric ?-Satellite RNAs. The FEBS journal, 289(7), 1858.

Massó-Vallés D, et al. (2022) MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer research communications, 2(2), 110.

Palve V, et al. (2022) The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell chemical biology, 29(2), 202.

Peck B, et al. (2021) 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer research, 81(4), 847.

Villa E, et al. (2021) mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis. Molecular cell, 81(10), 2076.

Zonneville J, et al. (2021) Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Communications biology, 4(1), 862.

Cie?la M, et al. (2021) Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. Molecular cell, 81(7), 1453.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell systems, 12(5), 401.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell chemical biology, 27(10), 1229.